Who are Ivermectin 1% cream's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ''albendazole'' and ''ivermectin'', Ivermectin 1% cream (IVM), Oral ivermectin, Ivermectin + colchicine, Ivermectin 0.1% Metronidazole 1%, Ivermectin (reference).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ivermectin-1-cream.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Ivermectin 1% cream — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ivermectin 1% cream (Ivermectin 1% cream) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiparasitic agent. Area: Dermatology.

marketed Antiparasitic agent Glutamate-gated chloride channels Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Ivermectin 1% cream (Ivermectin 1% cream) — Insel Gruppe AG, University Hospital Bern. Ivermectin binds to glutamate-gated chloride channels in parasites and arthropods, causing paralysis and death of the organisms.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Ivermectin 1% cream TARGET	Ivermectin 1% cream	Insel Gruppe AG, University Hospital Bern	marketed	Antiparasitic agent	Glutamate-gated chloride channels
''albendazole'' and ''ivermectin''	''albendazole'' and ''ivermectin''	Centre d'Appui à la lutte contre la Maladie	marketed	Antihelmintic/Antiparasitic agents	β-tubulin (albendazole); glutamate-gated chloride channels (ivermectin)
Ivermectin 1% cream (IVM)	Ivermectin 1% cream (IVM)	Galderma R&D	marketed	Antiparasitic agent	Glutamate-gated chloride channels (invertebrate-specific)
Oral ivermectin	Oral ivermectin	University of Oxford	marketed	Macrocyclic lactone antiparasitic	Glutamate-gated chloride channels (GluCl)
Ivermectin + colchicine	Ivermectin + colchicine	Ain Shams University	marketed	Antiparasitic + anti-inflammatory combination	Glutamate-gated chloride channels (ivermectin); tubulin/microtubules (colchicine)
Ivermectin 0.1% Metronidazole 1%	Ivermectin 0.1% Metronidazole 1%	Universidad Nacional de Colombia	phase 3	Antiparasitic/Antimicrobial combination	Glutamate-gated chloride channels (ivermectin); DNA/anaerobic metabolism (metronidazole)
Ivermectin (reference)	Ivermectin (reference)	Padagis LLC	phase 3	Antiparasitic agent	Glutamate-gated chloride channels (GluCl)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiparasitic agent class)

Actavis Inc. · 2 drugs in this class
Galderma R&D · 1 drug in this class
Insel Gruppe AG, University Hospital Bern · 1 drug in this class
Padagis LLC · 1 drug in this class
U.S. Army Medical Research and Development Command · 1 drug in this class
University of Brasilia · 1 drug in this class
University of Oxford · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ivermectin 1% cream — Competitive Intelligence Brief. https://druglandscape.com/ci/ivermectin-1-cream. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing